Literature DB >> 18287220

Experimental autoimmune prostatitis induces chronic pelvic pain.

Charles N Rudick1, Anthony J Schaeffer, Praveen Thumbikat.   

Abstract

Pain is the hallmark of patients with chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS). Despite numerous hypotheses, the etiology and pathogenesis remain unknown. To better understand CP/CPPS, we used a murine experimental autoimmune prostatitis model to examine the development, localization, and modulation of pelvic pain. Pelvic pain was detected 5 days after antigen instillation and was sustained beyond 30 days, indicating the development of chronic pain. The pain was attenuated by lidocaine treatment into the prostate, but not into the bladder or the colon, suggesting that pain originated from the prostate. Experimental autoimmune prostatitis histopathology was confined to the prostate with focal periglandular inflammatory infiltrates in the ventral, dorsolateral, and anterior lobes of the mouse prostate. Inflammation and pelvic pain were positively correlated and increased with time. Morphologically, the dorsolateral prostate alone showed significantly increased neuronal fiber distribution, as evidenced by increased protein gene product 9.5 expression. Pelvic pain was attenuated by treatment with the neuromodulator gabapentin, suggesting spinal and/or supraspinal contribution to chronic pain. These results provide the basis for identifying mechanisms that regulate pelvic pain and the testing of therapeutic agents that block pain development in CP/CPPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287220     DOI: 10.1152/ajpregu.00836.2007

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  39 in total

1.  Uropathogenic Escherichia coli induces chronic pelvic pain.

Authors:  Charles N Rudick; Ruth E Berry; James R Johnson; Brian Johnston; David J Klumpp; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Defining the Urological Chronic Pelvic Pain Syndromes.

Authors:  Andrew Baranowski
Journal:  Rev Pain       Date:  2008-12

Review 3.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

Review 4.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

5.  Experimental autoimmune prostatitis induces microglial activation in the spinal cord.

Authors:  Larry Wong; Joseph D Done; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Prostate       Date:  2014-09-27       Impact factor: 4.104

6.  CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis.

Authors:  Marsha L Quick; Soumi Mukherjee; Charles N Rudick; Joseph D Done; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-18       Impact factor: 3.619

7.  Role of mast cells in male chronic pelvic pain.

Authors:  Joseph D Done; Charles N Rudick; Marsha L Quick; Anthony J Schaeffer; Praveen Thumbikat
Journal:  J Urol       Date:  2012-02-17       Impact factor: 7.450

Review 8.  Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.

Authors:  Yuqian Liu; Junaid Wazir; Meng Tang; Rahat Ullah; Yueting Chen; Tingting Chen; Xiaohui Zhou
Journal:  Int Urol Nephrol       Date:  2020-11-16       Impact factor: 2.370

9.  Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation.

Authors:  Isabella M Fuentes; Angela N Pierce; Pierce T O'Neil; Julie A Christianson
Journal:  J Vis Exp       Date:  2015-08-13       Impact factor: 1.355

10.  Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis.

Authors:  Charles N Rudick; Anthony J Schaeffer; David J Klumpp
Journal:  BMC Urol       Date:  2009-11-12       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.